Thermo Fisher Scientific Inc (TMO)vsWaters Corporation (WAT)
TMO
Thermo Fisher Scientific Inc
$651.45
-1.04%
HEALTHCARE · Cap: $225.48B
WAT
Waters Corporation
$421.63
-1.88%
HEALTHCARE · Cap: $39.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Thermo Fisher Scientific Inc generates 898% more annual revenue ($46.34B vs $4.64B). TMO leads profitability with a 15.0% profit margin vs 3.6%. WAT appears more attractively valued with a PEG of 1.52. TMO earns a higher WallStSmart Score of 60/100 (C+).
TMO
Buy60
out of 100
Grade: C+
WAT
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.3%
Fair Value
$345.90
Current Price
$651.45
$305.55 premium
Margin of Safety
-45.9%
Fair Value
$225.66
Current Price
$421.63
$195.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 1.7B in free cash flow
Revenue surging 113.4% year-over-year
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
ROE of 1.1% — below average capital efficiency
3.6% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : TMO
The strongest argument for TMO centers on Market Cap, Free Cash Flow. Revenue growth of 10.5% demonstrates continued momentum.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score, Price/Book. Revenue growth of 113.4% demonstrates continued momentum.
Bear Case : TMO
The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Return on Equity, Profit Margin. A P/E of 102.5x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
TMO profiles as a value stock while WAT is a hypergrowth play — different risk/reward profiles.
WAT carries more volatility with a beta of 1.19 — expect wider price swings.
WAT is growing revenue faster at 113.4% — sustainability is the question.
TMO generates stronger free cash flow (1.7B), providing more financial flexibility.
Bottom Line
TMO scores higher overall (60/100 vs 45/100) and 10.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Thermo Fisher Scientific Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.
Visit Website →Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?